POAI - מזומני החברה predictive-oncology.com

The development of AI tools for oncology is not subject to cycles, and the success of Predictive Oncology (POAI) relies on the R&D budgets of pharmaceutical giants. The cash asset volume metric, which forms this chart via GURU.Markets data, serves as a liquidity indicator, where the value of 0.00 determines this level. However, extreme pressure from IT behemoths creates serious barriers to business development.
פילוחי מדדים פיננסיים ומדדי שוק עבור Predictive Oncology (POAI)

This indicator tracks the actual balance of liquid assets in the issuer's accounts, allowing investors to filter out speculative noise and assess the business's real solvency through GURU.Markets tools. By analyzing the company's cash reserves, one can determine the extent to which Predictive Oncology (POAI) is capable of sustaining the development of AI platforms while remaining dependent on the R&D budgets of pharma behemoths and maintaining strict control over operating expenses.